Gene therapy for gliomas: P53 and E2F-1 proteins and the target of apoptosis (Review)

International Journal of Molecular Medicine

Volumn 3, Issue 1, 1999, Pages 81-85

  Gomez Manzano, Candelaria ^a   Fueyo, Juan ^a   Alameda, Francisco ^b   Kyritsis, Athanassios P ^a   Yung, W K Alfred ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; E2F 1; Gene therapy; Gliomas; p53

Indexed keywords

CARRIER PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; E2F1 PROTEIN, HUMAN; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; GLIOMA; HUMAN; REVIEW;

APOPTOSIS; CARRIER PROTEINS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLIOMA; HUMANS; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032608285     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. James C, Carlbom E, Dumanski J, Hansen M, Nordenskjold M, Collins VP and Cavenee WK: Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546-5551, 1998.
2. Nigro JM, Baker SJ and Preisinger AC: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
3. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W and yogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992.
4. Pults D, Brockmeyer D, Tullous MW, Pedone CA and Cawthon RM: p53 mutations and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52: 674-679, 1992.
5. Anker L, Ohgaki H, Ludeke BI, Herrmann H-D, Kleihues P and Westphal M: p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 55: 982-987, 1993.
6. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Wison JKV, Kinzler W and Volgestein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994.
7. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994.
8. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WKA and Kyritsis AP: Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13: 1615-1619, 1996.
9. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA and Bruner J: Mutations of the p16 gene in gliomas, Oncogene 12: 63-67, 1996.
10. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A and Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153, 1996.
11. Hamel W, Westphal M and Shepard HM: Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease. J Neurooncol 16: 159-165, 1993.
12. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu HJ, Benedict WF, Yandell DW and Louis DN: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36: 714-721, 1994.
13. Hirvonen HE, Salonen R, Sandberg MM, Vourio E, Vadstrik I, Kotilainen E and Kalimo H: Differential expression of myc, max and RB1 genes in human gliomas and glioma cell lines. Br J Cancer 69: 16-25, 1994.
14. Maxwell M, Galanopoulos T and Antoniades HN: Cell-cycle regulator cyclin D1 mRNA and protein overexpression occurs in primary malignant gliomas. Int J Oncol 9: 493-497, 1996.
15. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III and James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994.
16. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1946, 1997.
17. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV: Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
18. Mollenhauer J, Weimann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A and Postka A: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumors. Nat Genet 17: 32-39, 1997.
19. Nakamura H, Yoshida M, Tsuiki H, Ito K, Ueno M, Nakao M, Oka K, Tada M, Kochi M, Kuratsu J, Ushio Y and Saya H: Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 16: 1009-1019, 1997.
20. Harris CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455, 1996.
21. Vogelstein B and Kinzler W: p53 function and disfunction. Cell 70: 523-526, 1992.
22. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1 a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
23. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 CDK-interacting protein Cip 1 is apotent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
24. 2/M and the G, cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497, 1995.
25. Xiong Y, Zhang H and Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514, 1992.
26. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
27. Sedlak TW, Oltavi ZN, Yang E, Wang K, Boise LH, Thompson CB and Korsmeyer SJ: Multiple bcl-2 familly members demonstrate selective dimerizations with bax. Proc Natl Acad Sci USA 92: 7834-7838, 1995.
28. Haupt Y, Rowan S and Oren M: p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10: 1563-1571, 1995.
29. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA and Yung WKA: Adenovirus-mediated transfer of p53 gene produces rapid and generalized death of human glioma cellls via apoptosis. Cancer Res 56: 694-699, 1996.
30. Polyak K, Waldman T, He T-C, Kinzler KW and Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945-1952, 1996.
31. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Orem M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991.
32. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B and Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992.
33. Kyritsis AP, Xu R, Bondy ML, Levin VA and Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog 15: 1-4, 1996.
34. WAF1/CiP1 in human brain tumors. Oncogene 11: 2021-2028, 1995.
35. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA and Yung WKA: Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 14: 1036-1044, 1997.
36. Wang J and Walsh K: Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 273: 359-361, 1996.
37. Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL and Ross AH: The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 16: 1335-1341, 1996.
38. Kovesdi I, Reichel R and Nevins JR: Identification of a cellular transcription factor involved in E1 A trans-activation. Cell 45: 219-228, 1986.
39. Helin K, Lees JA, Vidai M, Dyson N, Harlow E and Fattaey A: A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70: 337-350, 1992.
40. Kaelin WG Jr. Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ and Blanar MA: Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70: 351-364, 1992.
41. Shan B, Zhu X, Chen PL, Durfee T, Yang Y, Sharp D and Lee WH: Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F. Mol Cell Biol 12: 5620-5631, 1992.
42. Johnson DG, Schwarz JK, Cress WD and Nevins JR: Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365: 349-352, 1993.
43. Singh P, Wong SH and Hong W: Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 13: 3329-3338, 1994.
44. Qin XQ, Livingston DM, Kaelin WG and Adams PD: Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 91: 10918-10922, 1994.
45. Wu X and Levine AJ: p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91: 3602-3606, 1994.
46. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH and Greenberg ME: E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85: 549-561, 1996.
47. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E and Dyson NJ: Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-548, 1996.
48. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
49. Gomez-Manzano C, Fueyo J, Kyritsis AP and Yung WK: Tumor suppressor gene therapy for brain tumors. In: Gene Transfer and Therapy for Neurological Disorders. Chiocca AE and Breakefield X (eds). Human Press Inc., Totowa, NJ, pp201-225, 1998.
50. Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z and Kaelin WG Jr: The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol 15: 742-755, 1995.
51. Fueyo J, Gomez-Manzano C, Yung WKA, dayman GL, Liu T-J, Bruner JM, Levin VA and Kyritsis AP: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-110, 1996.
52. Fueyo J, Gomez-Manzano C, Yung WKA, Liu T-J, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA and Kyritsis AP: Suppression of human glioma growth by adenovirus mediated Rb gene transfer. Neurology 50: 1307-1315, 1998.
53. Fueyo J, Gomez-Manzano C, Yung WKA, Liu T-J, Alemany R, McDonnell TJ, Shi X, Rap JS, Levin VA and Kyritsis AP: Over-expression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and HI vivo. Nat Med 4: 685-690, 1998.
54. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG Jr and Fine HA: Tumor-selective transgene expression I'M vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3: 1145-1149, 1997.
55. Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K and Lu X: E2F-1-induced apoptosis requires DNA binding by not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 11: 1840-1852, 1997.